

Special Issue

Norovirus Vaccine

Message from the Guest Editors

Given the current surge in norovirus cases—one of the leading causes of acute gastroenteritis worldwide—there is an urgent need for effective vaccines to alleviate the significant social and economic burden of outbreaks. With multiple norovirus vaccines in progress, continued research is essential to accelerate vaccine development and maximize their potential public health impact.

We are pleased to invite you and your colleagues to submit a contribution to the Special Issue. It will cover the major continuing advances in the development of vaccines and immunotherapy treatment for noroviruses, including the following topics: **the design and characterization of potential vaccine antigens and candidates, the development of monoclonal antibodies, the testing of vaccine platforms and adjuvants in animals and humans, antiviral immunity, and the relationship between immune responses and viral pathogenesis.** Other related topics will also be considered, including **investigations aimed at understanding the challenges in current vaccines, broadly neutralizing antibodies, structural function analysis, and theoretical studies on vaccine design.**

Guest Editors

Prof. Dr. Akira Nakanishi

Department of Genetic Engineering, Faculty of Biology-Oriented Science and Technology, Kindai University, Higashiosaka City 577-8502, Japan

Prof. Dr. Kazuhiko Katayama

Laboratory of Viral Infection Control, Ōmura Satoshi Memorial Institute, Graduate School of Infection Control Sciences, Kitasato University, 5-9-1, Shirogane, Minato-ku 108-8641, Japan

Deadline for manuscript submissions

30 June 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/242532

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).